Over-Monitored and Under-Coordinated: Why Pharma Logistics Needs a Trusted Source of Record
As pharmaceutical manufacturers scale new therapies from clinical trials to commercial distribution, they encounter a problem that no amount of investment in cold chain infrastructure alone can solve: there is no single Trusted Source of Record across the pharma logistics value chain. Temperature excursions cost the pharmaceutical industry an estimated $35 billion annually — not because monitoring technology doesn't exist, but because the data it generates lives in siloed systems with no interoperability layer connecting them, turning what should be an automated coordinated response into a slow, manual process of bilateral communication across organizations.¹
The Problem in Plain Terms
Consider what it takes to move a monoclonal antibody therapy from manufacturing facility to patient. The journey touches every participant in the pharma logistics value chain — the pharmaceutical manufacturer, the contract development and manufacturing organization (CDMO), the specialty courier, the global logistics carrier, the cold chain packaging provider, the temperature and sensor device monitoring the shipment in transit, the customs broker, the 3PL warehouse, and ultimately the patient.
Each of these parties has visibility into their own leg of the journey. None has reliable, real-time visibility into the full chain.
The result is a logistics network that is simultaneously over-monitored and under-coordinated.
Temperature sensors generate condition data. GPS trackers generate location pings. Specialty couriers log chain of custody events. But that data lives in siloed systems, owned by different parties, formatted differently, and shared selectively — if at all. Nearly every major participant operates its own control tower — monitoring exceptions within their own network.
The problem is not that local operators lack awareness — real-time sensors and monitoring systems ensure they know when something is wrong. The problem is what happens next. The authority to act, the approved protocol to follow, and the simultaneous awareness of every other party in the chain needed to coordinate a response are fragmented across organizations with no shared information layer. By the time the excursion is fully understood by all parties, the window to intervene may have closed.
Why This Matters More Now Than Ever
For traditional pharmaceutical products, this fragmentation was manageable. Products had long shelf lives, distribution networks were established and predictable, and the consequences of a delay, while costly, were rarely catastrophic.
The new generation of therapies operates under entirely different constraints — and those constraints vary significantly by therapy class, which makes the coordination challenge even harder.
Diagnostic radioligand therapies have half-lives measured in hours — a missed connection or customs delay doesn't just inconvenience the supply chain, it renders the product clinically useless. Cell and gene therapies are often patient-specific: a dose manufactured for a named patient, at a named facility, on a named treatment date. A failed delivery cannot simply be replaced from inventory. Monoclonal antibodies and biologics require strict temperature control across global distribution networks — and unlike many conventional drugs, a temperature excursion in a biologic shipment leaves no visible sign of degradation. The product looks identical whether it is intact or compromised.
Across all of these therapy classes, the stakes of a logistics failure have risen from costly to catastrophic. Without a verified, shared record of chain of condition and chain of custody across every handoff, a compromised product can reach a patient undetected — and a logistics operator cannot demonstrate regulatory compliance when something goes wrong. The absence of a Trusted Source of Record is not an inconvenience. It is a patient safety risk and a regulatory liability.
The regulatory pressure is compounding this urgency across major pharmaceutical markets. The WHO's Good Distribution Practice (GDP) guidelines — enforced regionally by the European Medicines Agency (EMA) across the EU and by the FDA in the United States — establish the international standard governing temperature-controlled storage, transport documentation, deviation management, and distribution traceability. Non-GDP-compliant architectures now carry existential operational and regulatory risk for any participant in the chain — regardless of where they operate.²
Visibility Is Necessary. Resilience Is the Point.
Knowing that something is wrong is not the same as being able to fix it. The gap between visibility and operational resilience is where most pharma logistics failures actually occur — not in the monitoring, but in the response.
Individual carrier networks have made meaningful progress here. UPS® Premier, for example, combines real-time IoT monitoring with automated escalation workflows, predictive excursion analytics, and active intervention capability within its own network. The visibility exists. The capability exists — within the boundary of a single carrier's network. The gap is what happens at the handoff points between parties, and what happens at the moment of truth when a critical shipment is in distress.
At that moment, three things determine whether the payload is saved or lost:
Condition and location information — does the operator handling the shipment at that precise point in the chain have real-time, verified data on what is happening to the product right now — its temperature, its location, its custody status — not just within their own network leg, but across the full chain context needed to make an informed decision?
Knowledge to act — does the operator have immediate access to the product-specific excursion management protocol for this shipment — the acceptable deviation window, the pre-approved intervention steps, the manufacturer's SOP — without having to initiate a manual request across organizational boundaries while the clock is running?
Authority to act — does the operator have the pre-authorized mandate to execute an intervention immediately — reroute, source emergency cold storage, dispatch a replacement courier, trigger a disposition protocol — without waiting for a quality assurance approval from the manufacturer that requires waking someone up, escalating through multiple organizational layers, and obtaining a documented decision from a party working from incomplete information?
When all three are present and pre-agreed across every party in the chain, payloads are saved. When any one is missing — and today, across a multi-party pharma logistics value chain, at least one almost always is — time runs out before the chain can coordinate a response. For the most time-critical therapies, that delay is not a commercial inconvenience. It is a clinical failure.
This is the operational case for a Trusted Source of Record — not just a platform that sees what is happening, but a shared layer that gives every authorized operator, at every point in the chain, the condition and location data, the product-specific knowledge, and the pre-authorized mandate to act in the moment that matters.
What a Trusted Source of Record Would Look Like
A Trusted Source of Record in pharma logistics — a concept JP Strategies defines as a single, shared, tamper-proof information layer that provides every authorized participant in the value chain with the data they need, when they need it, to make confident decisions about product integrity, custody, and compliance — would provide three things simultaneously:
Chain of custody — a tamper-proof, real-time record of who had the product, when, and under what authorization, at every handoff from manufacturing to patient.
Chain of condition — a continuous, verified record of the product's physical state throughout transit — temperature, humidity, shock — with alerts triggered before excursions become irreversible, across every leg of the journey regardless of which carrier or courier is handling it.
Secure collaboration — the ability for every authorized party in the chain to access the information they need, when they need it, without compromising proprietary data or regulatory standing. The hospital receiving dock, the specialty courier, the global logistics carrier, and the pharma manufacturer should all be operating from the same trusted data — not reconciling conflicting records after the fact.
These three elements must work together. Chain of condition data without chain of custody is monitoring without accountability. Chain of custody without chain of condition is compliance theater. And neither has value without a collaboration layer that makes the data accessible to the people who need it, in time to act on it.
The Technology Landscape
The market is developing solutions at two distinct layers — and understanding the distinction matters for investors evaluating assets in this space.
The first is the monitoring and sensing layer — hardware and software that captures real-time condition and location data across the value chain. This is a relatively mature market. Sensitech (a Carrier Global subsidiary) holds the largest market share in pharmaceutical cold chain monitoring, offering device-agnostic platforms and automated compliance tools through its Lynx platform.³ Controlant and Tive are strong challengers, each offering real-time IoT tracking purpose-built for temperature-sensitive pharma and biologics. SkyCell — better known for its hybrid temperature-controlled containers — has extended its platform into real-time pharma monitoring and AI-powered analytics through its SkyMind solution, positioning itself at the intersection of hardware and software in the cold chain visibility space. These platforms are well-established — the challenge they address is data capture, not data integration or multi-party coordination.
The second is the orchestration and network layer — platforms that sit above the monitoring infrastructure and attempt to coordinate data, decisions, and compliance records across multiple parties in the value chain. This is considerably less mature, and significantly more strategically important. Two types of players are building here. Established network platforms like TraceLink have leveraged regulatory compliance mandates to build large connected partner networks, and are now expanding those networks beyond compliance into multi-enterprise supply chain orchestration across transportation, logistics, and commercial operations.⁴ Emerging purpose-built platforms like KatalX are approaching the same layer from a different angle — designing specifically for the Precision Logistics use case, combining chain of custody, chain of condition, chain of identity, and secure multi-party collaboration into an integrated layer built for the clinical-to-commercial transition of advanced therapies. The strategic question for investors is which approach — network scale built on compliance infrastructure, or purpose-built Precision Logistics orchestration — creates the more defensible position as therapy volumes scale.
The challenge at both layers is adoption. A Trusted Source of Record only works if every party in the chain participates — and getting manufacturers, CDMOs, specialty couriers, global carriers, packaging companies, and hospital systems to share data on a common platform requires trust, interoperability standards, and regulatory alignment that the industry is still building toward. GDP enforcement is accelerating that alignment on the compliance side. The commercial and clinical supply chain coordination problem remains largely unsolved.
The Investment Angle
For investors evaluating assets in the pharma logistics space, the Trusted Source of Record question is increasingly relevant to diligence — at two levels.
At the asset level: target companies that can demonstrate genuine chain of custody and chain of condition capability — not just GPS tracking and temperature logging — are better positioned for the regulatory and commercial demands of the next generation of therapies. The gap between "we have monitoring" and "we have a trusted, auditable source of record" is where the defensible value lies.
At the platform level: the orchestration layer is early but real, and the competitive dynamics are worth understanding. Established network platforms bring regulatory credibility and partner-network scale built over years of compliance mandates. Purpose-built Precision Logistics platforms bring speed, domain specificity, and architectures designed from the ground up for the clinical-to-commercial transition. Each has genuine strengths; neither has yet demonstrated a complete solution. The question of who ultimately owns the Trusted Source of Record in pharma logistics — and what that ownership is worth as therapy volumes scale — may be one of the more consequential investment questions in this space over the next decade.
The Bottom Line
The pharma logistics infrastructure of the past was built for a world of stable, long-lived products moving through predictable networks. The therapies now reaching commercial scale — radioligand, cell and gene, mRNA, biologics — demand something fundamentally different: a logistics system that knows where every dose is, what condition it is in, and who has had custody of it, in real time, across every party in the chain — from the manufacturer's loading dock to the patient's bedside.
That system — the Trusted Source of Record — does not yet fully exist. Building it, or investing in the companies building it, is where the next chapter of Precision Logistics begins.
Sources
¹ IQVIA Institute for Human Data Science, Biopharma Cold Chain Logistics Survey, 2019, as cited in Pharmaceutical Commerce, Why the U.S. Pharmaceutical Cold Chain Is Poised for Innovation, April 2026. pharmaceuticalcommerce.com
² European Medicines Agency, Guidelines on Good Distribution Practice of Medicinal Products for Human Use, 2013 (as updated). ema.europa.eu; WHO Technical Report Series No. 961, Annex 9, Model Guidance for the Storage and Transport of Time and Temperature–Sensitive Pharmaceutical Products. who.int
³ MarketsandMarkets, Cold Chain Monitoring Market Size, Share, Industry Trends 2030, 2025. marketsandmarkets.com
⁴ TraceLink, TraceLink Builds on Transformative 2025 to Scale Agentic Orchestration Across the Global Life Sciences Supply Chain in 2026, February 27, 2026. prnewswire.com/news-releases/tracelink-builds-on-transformative-2025-to-scale-agentic-orchestration-across-the-global-life-sciences-supply-chain-in-2026-302699828.html
Jim Poole is the founder of JP Strategies LLC, a deal advisory firm serving private equity and executive search firms in healthcare logistics, parcel, and last-mile markets. He previously served as Healthcare Strategy Director at UPS.
